Spero Therapeutics (SPRO) Research & Development (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Research & Development came in at $2.9 million in Q1 2026, down 78.62% YoY from $13.6 million in Q1 2025, and down 47.98% on a QoQ basis from $5.6 million in Q4 2025.
Spero Therapeutics (SPRO) Research & Development (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Research & Development data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Research & Development fell 78.62% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (down 70.15% YoY) and the FY2025 annual result came in at $38.5 million, down 60.24% from the prior year.
- Research & Development slipped to $2.9 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $28.8 million in Q4 2024 to a low of $2.9 million in Q1 2026.
- A 5-year average of $14.0 million and a median of $13.6 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 149.47% — and 2025, when it plunged 80.61%.
- Tracing SPRO's Research & Development over 5 years: stood at $15.1 million in 2022, then gained by 9.73% to $16.6 million in 2023, then jumped by 74.16% to $28.8 million in 2024, then sank by 80.61% to $5.6 million in 2025, then slumped by 47.98% to $2.9 million in 2026.
- The last three Research & Development figures came in at $2.9 million (Q1 2026), $5.6 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.43 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 5.59 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Jun 30, 2025 | 10.67 Mn |
| Mar 31, 2025 | 13.61 Mn |
| Dec 31, 2024 | 28.84 Mn |
| Sep 30, 2024 | 26.86 Mn |
| Jun 30, 2024 | 23.73 Mn |
| Mar 31, 2024 | 17.33 Mn |
| Dec 31, 2023 | 16.56 Mn |
| Sep 30, 2023 | 16.39 Mn |
| Jun 30, 2023 | 9.51 Mn |
| Mar 31, 2023 | 8.98 Mn |
| Dec 31, 2022 | 15.09 Mn |
| Sep 30, 2022 | 7.36 Mn |
| Jun 30, 2022 | 8.17 Mn |
| Mar 31, 2022 | 16.97 Mn |
| Dec 31, 2021 | 17.23 Mn |
| Sep 30, 2021 | 14.44 Mn |